Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma
文献类型：期刊论文
| 作者 | Long, Hezhou3,4; Zhou, Jiafu3,4; Zhou, Changxia2; Xie, Shuyu1,2; Wang, Jingling3; Tan, Minjia1,2,3,4 ; Xu, Junyu1,2,3,4
|
| 刊名 | BIOMEDICINES
 |
| 出版日期 | 2025 |
| 卷号 | 13期号:1页码:20 |
| 关键词 | proteomics hepatocellular carcinoma hepatocellular carcinoma-targeted drugs S/T/Y phosphorylation drug combination |
| DOI | 10.3390/biomedicines13010152 |
| 英文摘要 | Background/Objectives: Hepatocellular carcinoma (HCC) remains a significant global health concern, primarily due to the limited efficacy of targeted therapies, which are often compromised by drug resistance and adverse side effects. Methods: In this study, we utilized a Tandem Mass Tag (TMT)-based quantitative proteomic approach to analyze global protein expression and serine/threonine/tyrosine (S/T/Y) phosphorylation modifications in HepG2 cells following treatment with three clinically relevant hepatocellular carcinoma-targeted agents: apatinib, regorafenib, and lenvatinib. Results: Utilizing KEGG pathway enrichment analysis, biological process enrichment analysis, and protein interaction network analysis, we elucidated the common and specific metabolic pathways, biological processes, and protein interaction regulatory networks influenced by three liver cancer therapeutics. The study additionally proposed potential combinational treatment strategies, highlighting a possible synergistic interaction between HCC-targeted drugs and the DNA methyltransferase inhibitor. Furthermore, through the integration of clinical phosphorylation site data, we identified several phosphorylation sites that exhibited higher abundance in tumor tissues compared to adjacent non-tumor tissues. These sites were associated with poor prognosis and elevated functional scores. Conclusions: In summary, this study conducted an in-depth analysis of the molecular alterations in proteins and phosphorylation modifications induced by clinical HCC-targeted drugs, predicting drug combination strategies and therapeutic targets. |
| WOS关键词 | REGORAFENIB ; SORAFENIB ; PATHWAYS |
| 资助项目 | National Key Research and Development Program of China[2023YFA1800400] ; National Key Research and Development Program of China[2023YFA1800403] ; Shanghai Academic Research Leader Program[22XD1420900] ; Innovative Research Team of High-Level Local Universities in Shanghai[SHSMU-ZDCX20212700] ; National Natural Science Foundation of China[32322048] ; National Natural Science Foundation of China[32471497] ; Young Elite Scientists Sponsorship Program by CAST[2022QNRC001] ; Shanghai Rising-Star Program[22QA1411100] ; Youth Innovation Promotion Association[CAS2021276] ; Sanofi scholarship program ; Guangdong High-level New R&D Institute, China[2019B090904008] ; Guangdong High-level Innovative Research Institute, China[2021B0909050003] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Research & Experimental Medicine ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001404563100001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/315929]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Tan, Minjia; Xu, Junyu |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China 3.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China 4.Southern Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China |
| 推荐引用方式 GB/T 7714 | Long, Hezhou,Zhou, Jiafu,Zhou, Changxia,et al. Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma[J]. BIOMEDICINES,2025,13(1):20. |
| APA | Long, Hezhou.,Zhou, Jiafu.,Zhou, Changxia.,Xie, Shuyu.,Wang, Jingling.,...&Xu, Junyu.(2025).Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma.BIOMEDICINES,13(1),20. |
| MLA | Long, Hezhou,et al."Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma".BIOMEDICINES 13.1(2025):20. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。